Last updated: 4 months ago
Citius Oncology Q4 2024 Financial Report: Losses Mount Amid R&D Investments
Explore Citius Oncology's Q4 2024 financial analysis, highlighting a $21.15M net loss, $112 cash, and crucial R&D commitments. Investors advised to hold amidst uncertainties.